TFAP2C drives cisplatin resistance in bladder cancer by upregulating YAP and activating β-catenin signaling.

ABSTRACT: Cisplatin-based chemotherapy is a conventional therapy for muscle-invasive bladder cancer (BC); however, its efficacy is often limited by the emergence of resistance to cisplatin. Yes-associated protein (YAP) and β-catenin are involved in this resistance, yet their upstream regulators are not well defined. This study investigates the role of TFAP2C in regulating YAP expression and its impact on cisplatin resistance in BC. The Cancer Genome Atlas (TCGA) gene expression data and GSE231835 dataset were analyzed to identify potential transcription factors regulating YAP. Assessed TFAP2C and YAP expression in clinical samples and cell lines. Functional assays were performed following TFAP2C knockdown. Dual-luciferase reporter assays and Chromatin immunoprecipitation (ChIP) confirmed TFAP2C bind

SUBMITTER: Pan Q 

PROVIDER: S-EPMC12284524 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature